logo

For the Inventor, By the Inventor

Philadelphia, PA, United States of America

Fox Chase Cancer Center


USPTO Granted Patents = 81



Trademarks = 5

Forward Citations = 1,126

Loading Chart...
Loading Chart...

113 inventors (with patents filed for the assignee):

goldMedal Erica A Golemis (11 out of 17 patents)

silverMedal Gregory P Adams (8 out of 11 patents)

bronzeMedal Louis M Weiner (7 out of 12 patents)

4.  Eva M Horak (5 out of 6 patents)

5.  Truman R Brown (5 out of 6 patents)

6.  James David Marks (5 out of 81 patents)

7.  Alfonso Bellacosa (4 out of 8 patents)

8.  Ilya G Serebriiskii (4 out of 7 patents)

9.  Kerry S Campbell (4 out of 5 patents)

10.  Francis Kappler (4 out of 7 patents)

11.  Joanne Estojak (4 out of 4 patents)

12.  Christoph Seeger (4 out of 4 patents)

13.  Heidi H Simmons (3 out of 3 patents)

14.  Margie Clapper (3 out of 4 patents)

15.  Anthony T Yeung (3 out of 5 patents)


Core Competencies:
EGFR/NEDD9/TGF-β Interactome
Anti-Mullerian Inhibiting Substance Type II Receptor
Patient Positioning System
Endoscopic Examination
FAP Inhibitors
Genetically Modified Human Natural Killer Cell Lines
Combination Therapy
Bispecific Antibody Molecules
Organogenesis Promotion
Laser-Accelerated Proton Therapy
Angiogenesis Inhibition
DNA Repair Enzyme

81 patents:

1. 10450613 - EGFR/NEDD9/TGF-β interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders (2019-10-22),
2. 9611321 - Rationally-designed anti-mullerian inhibiting substance type II receptor antibodies (2017-04-04),
3. 9522078 - Patient positioning system and method for positioning a patient during a surgical procedure (2016-12-20),
4. 9451904 - Method and apparatus for endoscopic examination of lesions (2016-09-27),
5. 9346814 - FAP inhibitors (2016-05-24),
6. 9296687 - Modulators of HSP70/DnaK function and methods of use thereof (2016-03-29),
7. 9181322 - Genetically modified human natural killer cell lines (2015-11-10),
8. 9150636 - Genetically modified human natural killer cell lines (2015-10-06),
9. 9101631 - Combination therapy based on SRC and aurora kinase inhibition for the treatment of cancer (2015-08-11),
10. 8980258 - Bispecific single chain Fv antibody molecules and methods of use therof (2015-03-17),
11. 8802432 - Methods and cell cultures for promoting organogenesis and tissue development (2014-08-12),
12. 8748373 - Hepatitis B virus compositions and methods of use (2014-06-10),
13. 8685658 - Compositions and methods for the treatment of diseases associated with aberrant cilia assembly and regulation (2014-04-01),
14. 8658655 - Inhibition of activated cdc42-associated kinase 1 (2014-02-25),
15. 8653324 - TetO-p16 transgenic mice (2014-02-18),
Fox Chase Cancer Center is a National Cancer Institute-designated comprehensive cancer center located in Philadelphia, Pennsylvania. It is part of the Temple University Health System and specializes in the prevention, diagnosis, and treatment of cancer. Established in 1904, Fox Chase Cancer Center has a rich history of innovative research, exceptional patient care, and education. The center offers a wide range of advanced treatment options, conducts cutting-edge cancer research, and provides compassionate care to patients and their families.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

...
81 Patents

#26 in Philadelphia, PA

#168 in Pennsylvania

#4,424 in US

#9,095 in the World

...
Philadelphia, PA, United States of America

Fox Chase Cancer Center

Forward Citations = 1,126

113 inventors:

goldMedal Erica A Golemis (11 out of 17 patents)

silverMedal Gregory P Adams (8 out of 11 patents)

bronzeMedal Louis M Weiner (7 out of 12 patents)

4.  Eva M Horak (5 out of 6 patents)

5.  Truman R Brown (5 out of 6 patents)

Please report any incorrect information to support@idiyas.com
Loading…